Skip to main content
PepStack
Blutwerte · Marker

FSH

Follikelstimulierendes Hormon · Follicle-Stimulating Hormone · FSH

Hormone — ReproduktionsachseZeitabhängig
Einheit:
IU/L

FSH quantifies the concentration of follicle-stimulating hormone in the blood, reflecting pituitary function and gonadal activity.

Reference Ranges

Age Group

Reference
1.5–12.4IU/L
1.5
12.4
LowNormalHigh
Reference
Unit · IU/L

Reference ranges vary by sex and age; levels fluctuate during menstrual cycle in women.

Overview

Übersicht

Follicle-stimulating hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in the regulation of the reproductive processes, including the development of ovarian follicles in women and spermatogenesis in men. FSH acts by binding to specific receptors on the surface of target cells in the ovaries and testes, stimulating the production of sex steroids and gametes. Clinically, FSH is an important marker in the evaluation of reproductive health. Elevated FSH levels can indicate primary gonadal failure, such as in conditions like menopause or testicular failure, whereas low levels may suggest secondary hypogonadism due to pituitary or hypothalamic dysfunction. In athletes and biohackers, FSH levels can be indicative of overall reproductive health and hormonal balance. However, FSH is not typically a direct target for enhancing athletic performance or longevity. Researchers have explored FSH-blocking therapies for conditions like osteoporosis, suggesting a broader role beyond reproduction. Testing for FSH levels can be influenced by several factors, including time of day, as levels may vary throughout the day. It is important to consider these variables when interpreting FSH results. Additionally, factors such as recent hormonal treatments or underlying endocrine disorders can confound FSH measurements. Therefore, careful consideration of clinical context and potential interfering factors is essential for accurate interpretation.

Klinische Bedeutung

Elevated FSH levels often indicate primary gonadal failure, such as menopause or testicular failure, while low levels may suggest secondary hypogonadism due to pituitary or hypothalamic dysfunction.

Dynamics

Trend Interpretation

Rising Values

Progressively rising FSH levels may indicate worsening gonadal function; re-test in 4-6 weeks if levels are outside the normal range.

Falling Values

Progressively falling FSH levels may suggest recovery of gonadal function or effective treatment of underlying conditions.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Primary ovarian insufficiency
  • Menopause
  • Testicular failure
  • Turner syndrome
  • Klinefelter syndrome
Cause

Low Levels

  • Hypothalamic dysfunction
  • Pituitary dysfunction
  • Hyperprolactinemia
  • Hypogonadotropic hypogonadism
  • Stress or illness
Protocol

How to Optimize

Lever

Lifestyle

  • Manage stress levels
  • Regular physical activity
  • Adequate sleep
Lever

Nutrition

  • Balanced diet with adequate protein
  • Omega-3 fatty acids
  • Zinc-rich foods
Lever

Supplementation

  • Vitamin D
  • Zinc

Note:

Consult a healthcare provider for personalized advice, especially if considering hormonal treatments.

Testing Guidelines

✓Fasting Not Required
🕐Time-Sensitive

FSH levels may vary throughout the day; consistency in timing is recommended.

Testing Frequency

Annually for reproductive health evaluation, more frequently if symptomatic.

Interfering Factors

  • Hormonal medications
  • Recent pregnancy
  • Acute illness

Related Peptides & Hormones

Luteinizing Hormone

Correlated with

hormone

Open Research Questions

Current research suggests that robust reference intervals for follicle-stimulating hormone (FSH) in various populations, particularly in women experiencing menopausal symptoms or undergoing hormone therapy, remain incomplete. Researchers have not yet established optimal FSH targets for conditions like osteoporosis and male infertility, where its role is critical. Additionally, unanswered clinical questions include the implications of elevated FSH levels in different contexts and the effects of FSH-blocking therapies on long-term health outcomes.

40 Research Publications

988

Total Citations

16

Human/RCT

4.5

Avg. Influence

2020

Latest

Sort
Filter
#01

Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer.

HumanInfluence28.0
385
Researchers established detailed reference values for luteinizing hormone, follicle-stimulating hormone (FSH), estradiol, and progesterone throughout the menstrual cycle. The study involved daily hormone measurements from volunteers and aimed to aid in the interpretation of reproductive hormone results. This work contributes to better understanding of hormonal fluctuations in women.
View on PubMed
#02

Clinical and laboratory predictors of clomiphene response.

HumanInfluence2.0
155
View on PubMed
#03

The menopause and aging, a comparative perspective.

ReviewInfluence6.0
130
This review examines the neuroendocrinology of menopause, comparing rodent models to human experiences. It highlights the hormonal changes and their implications, noting that while rodents show hypothalamic impairments affecting LH and FSH surges, similar irreversible changes are not evident in peri-menopausal women.
View on PubMed
#04

Pharmacokinetics of follicle-stimulating hormone: clinical significance.

ReviewInfluence1.0
64
Researchers reviewed the pharmacokinetics of follicle-stimulating hormone (FSH) and found that different FSH preparations have varying effects based on their sialic acid content. They emphasized the importance of monitoring FSH levels to optimize treatment outcomes during ovulation induction.
View on PubMed
#05

Genetic evaluation of male infertility.

ReviewInfluence4.0
56
Researchers emphasized the need for genetic testing in men with severe oligospermia or azoospermia to clarify infertility causes. They noted differences in FSH levels between obstructive and non-obstructive azoospermia, which guide appropriate genetic testing. The study highlights the evolving landscape of genetic analysis in male infertility.
View on PubMed
#06

FSH-blocking therapeutic for osteoporosis.

Animal
33
Researchers developed a first-in-class FSH-blocking antibody, MS-Hu6, which showed efficacy in preventing and treating osteoporosis in mice. The study reported that MS-Hu6 localized to bone and bone marrow and demonstrated a long half-life in humanized mice. The findings suggest potential for future human testing.
View on PubMed
#07

The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.

ReviewInfluence1.0
30
Researchers discussed the expression of the follicle-stimulating hormone receptor (FSHR) in tumor blood vessels of various genitourinary malignancies. The study suggests that targeting FSHR may have therapeutic potential in treating prostate cancer and other solid tumors.
View on PubMed
#08

A Comprehensive Review of Estradiol, Progesterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in the Context of Laboratory Medicine to Support Women's Health.

ReviewInfluence2.0
26
Researchers reviewed the roles of estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone (FSH) in women's health. They noted a lack of robust reference intervals for these hormones, which complicates clinical care. The study calls for collaborative efforts to better define these intervals for improved health outcomes.
View on PubMed
#09

Relationship between metabolic syndrome and follicle-stimulating hormone in postmenopausal women.

UnknownInfluence1.0
20
Researchers examined the relationship between follicle-stimulating hormone (FSH) levels and metabolic syndrome in postmenopausal women. They found that higher FSH levels were associated with better insulin sensitivity and lower incidence of metabolic syndrome.
View on PubMed
#10

Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies.

ReviewInfluence1.0
16
Researchers summarized evidence regarding the effects of FSH on bone metabolism, noting that while observational studies link FSH levels to bone loss, interventional studies have not demonstrated a direct effect. They concluded that current evidence does not support FSH as a regulator of bone or fat metabolism in humans.
View on PubMed

Clinical Trials (13)

13

Total Trials

1,185

Total Enrolled

Inhibin B/FSH Ratio as a Predictor of Testicular Pathology in NOA

NCT07415928COMPLETED
Sponsor

Elazıg Fethi Sekin Sehir Hastanesi

Enrollment

73

Started

2026

Primary outcome

Micro-TESE Sperm Retrieval Outcome

Azoospermia, NonobstructiveNon-obstructive Azoospermia

Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)

NCT06847282RECRUITING
Sponsor

University of Kansas Medical Center

Enrollment

80

Started

2025

Primary outcome

Pediatric FSHD-COM

Muscular Dystrophy, Facioscapulohumeral

Hypogonadotrophic Hypogonadism in Genetic Neurodevelopmental Conditions

NCT07049042RECRUITING
Sponsor

University of Sheffield

Enrollment

50

Started

2025

Primary outcome

Measurement of FSH

Genetic Neurodevelopmental Disorders

Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve

Sponsor

Xiaomei Shao

Enrollment

106

Started

2023

Primary outcome

changes of serum follicle-stimulating hormone (FSH) level

Diminished Ovarian Reserve

An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression

NCT06079567RECRUITING
Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

50

Started

2023

Primary outcome

Minimal clinical importance of the Motor Function Measure-32 (MFM-32) from Baseline (V1) to 18 months (V3)

Facioscapulohumeral Muscular Dystrophy Type 2

ADVANCED FSHD-COM: New Clinical Outcome Measures to Evaluate Non-ambulant FSHD Patients, a Pilot Study

NCT05453461ACTIVE_NOT_RECRUITING
Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

30

Started

2023

Primary outcome

Change of the Motor Function Measure-32 (MFM-32) from Baseline (T0) to 6 months (T6), 12 months (T12) and 24 months (M24)

Facioscapulohumeral Muscular Dystrophy

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

NCT04812912RECRUITING
Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

120

Started

2021

Primary outcome

Change in anti-Mullerian hormone (AMH), estradiol and FSH of oxaliplatin-induced gonadal toxicity in pre-menopausal female patients (<40y)

Colorectal CancerColorectal NeoplasmsColorectal Carcinoma

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

NCT04635891RECRUITING
Sponsor

University of Kansas Medical Center

Enrollment

450

Started

2020

Primary outcome

10m walk/run

FSHD

Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD

NCT02948244COMPLETED
Sponsor

Murdoch Childrens Research Institute

Enrollment

11

Started

2017

Primary outcome

Motor Function Measure for Neuromuscular disease

Facio-Scapulo-Humeral DystrophyFSHD2FSHD1

Influence of Laparoscopic Endometrioma Stripping Surgery on Serum Anti-mullerian Hormone Levels

Sponsor

Clinical Centre of Serbia

Enrollment

100

Started

2014

Primary outcome

Change of follicle-stimulating hormone (FSH)

Endometriosis

FSH-R : Diagnostic Application for Localized Tumors in Cancerology

NCT02860481TERMINATED
Sponsor

Institut Curie

Enrollment

95

Started

2013

Primary outcome

sensitivity of blood FSH R detection in cancer patients

Cancer

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165Phase 1/2COMPLETED
Sponsor

University of Washington

Enrollment

20

Started

2006

Primary outcome

Dutasteride can suppress the secretion of LH and FSH after four weeks of administration.

Contraception

Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

NCT00402935WITHDRAWN
Sponsor

Case Comprehensive Cancer Center

Enrollment

0

Started

2004

Primary outcome

Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels

LeukemiaLong-term Effects Secondary to Cancer Therapy in AdultsLong-term Effects Secondary to Cancer Therapy in ChildrenLymphomaSexual Dysfunction and InfertilitySexuality and Reproductive IssuesUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific

Publication Trend

Research publications about FSH over time

10total
1
'82
1
'88
1
'92
1
'06
1
'13
1
'21
1
'22
2
'25
1
'26

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer